Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases

Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction

(2019) Daniel A. Nation et al.   NATURE MEDICINE

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease

(2019) Dilan Athauda et al.   JAMA Neurology

Semaglutide is Neuroprotective and Reduces α-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson’s Disease

(2019) Liping Zhang et al.   Journal of Parkinsons Disease

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy

(2019) Fernando Gomez-Peralta et al.   Drug Design Development and Therapy

Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats

(2019) Ghada A. Badawi et al.   NEUROTOXICITY RESEARCH

Preventing dementia by preventing stroke: The Berlin Manifesto

(2019) Vladimir Hachinski et al.   Alzheimers & Dementia

Long-term liraglutide ameliorates nigrostriatal impairment via regulating AMPK/PGC-1a signaling in diabetic mice

(2019) Delin Ma et al.   BRAIN RESEARCH

GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice

(2019) Léa Décarie-Spain et al.   NEUROPHARMACOLOGY

GLP-1: Molecular mechanisms and outcomes of a complex signaling system

(2019) Nicholas K. Smith et al.   NEUROCHEMISTRY INTERNATIONAL

The Relevance of Insulin Action in the Dopaminergic System

(2019) Francesca Fiory et al.   Frontiers in Neuroscience

Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer’s Disease

(2019) Manuela Bomba et al.   JOURNAL OF ALZHEIMERS DISEASE

Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease

(2018) Hong-Yan Cai et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease

(2018) Jingjing Tai et al.   BRAIN RESEARCH

Neuroprotective effect of glucagon-like peptide-1 receptor agonist is independent of glycaemia normalization in type two diabetic rats

(2018) Irina Filchenko et al.   Diabetes & Vascular Disease Research

A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials

(2018) Vanita R. Aroda   DIABETES OBESITY & METABOLISM

Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats

(2018) Ying Yang et al.   Molecular Medicine Reports

Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice

(2018) Manuela Bomba et al.   NEUROBIOLOGY OF AGING

Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model

(2018) Liping Zhang et al.   NEUROPEPTIDES

Liraglutide ameliorates cognitive decline by promoting autophagy via the AMP-activated protein kinase/mammalian target of rapamycin pathway in a streptozotocin-induced mouse model of diabetes

(2018) Fei-Juan Kong et al.   NEUROPHARMACOLOGY

GLP-1 receptor agonists downregulate aberrant GnT-III expression in Alzheimer's disease models through the Akt/GSK-3β/β-catenin signaling

(2018) Ying Wang et al.   NEUROPHARMACOLOGY

What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis

(2018) Dilan Athauda et al.   Journal of Parkinsons Disease

Neuroprotection of rhGLP-1 in diabetic rats with cerebral ischemia/reperfusion injury via regulation of oxidative stress, EAAT2, and apoptosis

(2018) Yi Fang et al.   DRUG DEVELOPMENT RESEARCH

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

(2017) Dilan Athauda et al.   LANCET

Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes

(2017) Giovanna Muscogiuri et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson’s disease

(2017) Ghada A. Badawi et al.   INFLAMMOPHARMACOLOGY

The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action

(2016) Dilan Athauda et al.   DRUG DISCOVERY TODAY

Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model

(2016) Liqin Qi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology

(2016) Antonella Tramutola et al.   Expert Review of Neurotherapeutics

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease

(2016) Henrik H. Hansen et al.   PLoS One

Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist

(2016) Kenichi Katsurada et al.   Journal of Diabetes Investigation

In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

(2016) Michael Gejl et al.   Frontiers in Aging Neuroscience

Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology

(2016) Antonella Tramutola et al.   Expert Review of Neurotherapeutics

Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice

(2015) Paula L. McClean et al.   BEHAVIOURAL BRAIN RESEARCH

Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer’s Disease and Other Neurodegenerative Diseases

(2015) Valeria Calsolaro et al.   CNS DRUGS

Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats

(2015) Volkan Solmaz et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice

(2015) De-Lin Ma et al.   JOURNAL OF NEUROCHEMISTRY

Parkinson's disease

(2015) Lorraine V Kalia et al.   LANCET

Cognitive function in patients with diabetes mellitus: guidance for daily care

(2015) Paula S Koekkoek et al.   LANCET NEUROLOGY

Restoration of Cerebral and Systemic Microvascular Architecture in APP/PS1 Transgenic Mice Following Treatment with Liraglutide™

(2015) Patricia Kelly et al.   MICROCIRCULATION

Brain Insulin Administration Triggers Distinct Cognitive and Neurotrophic Responses in Young and Aged Rats

(2015) Clarissa B. Haas et al.   MOLECULAR NEUROBIOLOGY

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

(2015) W. Liu et al.   NEUROSCIENCE

Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease

(2015) Darleen A. Sandoval et al.   PHYSIOLOGICAL REVIEWS

Insulin Reverses the High-Fat Diet-Induced Increase in Brain A  and Improves Memory in an Animal Model of Alzheimer Disease

(2014) M. Vandal et al.   DIABETES

Lixisenatide rescues spatial memory and synaptic plasticity from amyloid β protein-induced impairments in rats

(2014) H.-Y. Cai et al.   NEUROSCIENCE

Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice

(2014) Rachael Lennox et al.   PEPTIDES

Alzheimer’s disease and insulin resistance: translating basic science into clinical applications

(2013) Fernanda G. De Felice   JOURNAL OF CLINICAL INVESTIGATION

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease

(2013) Paula L. McClean et al.   NEUROPHARMACOLOGY

Chronic Treatment with the GLP1 Analogue Liraglutide Increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model

(2013) Vadivel Parthsarathy et al.   PLoS One

GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence

(2012) A. R. Meloni et al.   DIABETES OBESITY & METABOLISM

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers

(2012) Theresa R. Bomfim et al.   JOURNAL OF CLINICAL INVESTIGATION

Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD and wild-type mice

(2012) F Masciopinto et al.   Cell Death & Disease

Snapin Mediates Incretin Action and Augments Glucose-Dependent Insulin Secretion

(2011) Woo-Jin Song et al.   Cell Metabolism

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

(2010) M. A. Nauck et al.   DIABETOLOGIA

Parkinson's disease: from monogenic forms to genetic susceptibility factors

(2009) S. Lesage et al.   HUMAN MOLECULAR GENETICS

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

(2009) Y. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intrameal Hepatic Portal and Intraperitoneal Infusions of Glucagon-Like Peptide-1 Reduce Spontaneous Meal Size in the Rat via Different Mechanisms

(2008) Elisabeth B. Rüttimann et al.   ENDOCRINOLOGY

GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid

(2008) Victor A. Gault et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease

(2008) Alexander Harkavyi et al.   Journal of Neuroinflammation

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling

(2008) Aileen M. Moloney et al.   NEUROBIOLOGY OF AGING

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease

(2007) Göran Bertilsson et al.   JOURNAL OF NEUROSCIENCE RESEARCH